Inventiva SA
NASDAQ:IVA
Inventiva SA
NASDAQ:IVA
Price:
3.3 USD
3.12%
Market Closed
Updated:
May 6, 2024
Section:
Relative Value
The Relative Value of one
IVA
stock under the Base Case scenario is
2.77
USD.
Compared to the current market price of 3.3 USD,
Inventiva SA
is
Overvalued by 16%.
Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Relative Valuation FAQ:
IVA
Relative Value
Base Case
2.77
USD
Overvaluation 16%
Valuation Multiples
Multiples Across Competitors
IVA Competitors Multiples
Inventiva SA Competitors
Inventiva SA Competitors
All Countries
| Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
|---|---|---|---|---|---|---|---|---|
| FR |
|
Inventiva SA
NASDAQ:IVA
|
168.1m USD | 9.6 | -1.5 | -1.7 | -1.7 | |
| US |
|
Abbvie Inc
NYSE:ABBV
|
285.6B USD | 5.3 | 59.3 | 12.9 | 19.6 | |
| US |
|
Amgen Inc
NASDAQ:AMGN
|
159.7B USD | 5.7 | 23.8 | 17.3 | 26 | |
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
104.4B USD | 8 | 26.4 | 17.8 | 19.6 | |
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
103.6B USD | 10.5 | 28.6 | 22.9 | 24 | |
| AU |
|
CSL Ltd
ASX:CSL
|
133.1B AUD | 6.2 | 35.6 | 21.6 | 26.7 | |
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
80.3B USD | 2.9 | 165.8 | 6.6 | 8.7 | |
| US |
|
Moderna Inc
NASDAQ:MRNA
|
45.9B USD | 6.7 | -9.7 | -10.5 | -8.9 | |
| US |
|
Seagen Inc
NASDAQ:SGEN
|
43.1B USD | 18.8 | -57.5 | -61.9 | -55.8 | |
| US |
|
Biogen Inc
NASDAQ:BIIB
|
32.1B USD | 3.3 | 27.5 | 14.1 | 17.6 | |
| KR |
|
Celltrion Inc
KRX:068270
|
39.2T KRW | 18 | 73.1 | 44.7 | 61.6 |
P/S Multiple
P/E Multiple
EV/EBITDA Multiple
EV/EBIT Multiple
You don't have any saved screeners yet
